269
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Comment on “Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study,” by Kahl et al., Cancer Investig.igation, 2005, 23(1), pp. 13–18

, Ph.D. , M.D. & , D.O.
Page 572 | Published online: 11 Jun 2009

References

  • Kahl, B S.; Bailey, H H.; Smith, E P.; Turman, N.; Smith, J.; Werndli, J.; Williams, E C.; Longo, W L.; Kim, K M.; McGovern, J.; Jumonville, A. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.Cancer Investig. 2005, 23 (1), 13–18. [CSA]
  • Borghaei, H.; Millenson, M.; Schilder, R.; Alden, M.; Rogatko, A.; Wang, H.; Padavic-Shaller, K.; Smith, M R. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.Cancer 2004, 101 (9), 2034–2041. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.